MARKET

CELG-RT

CELG-RT

Bristol-Myers Squibb Company Celegne Contingent Value Rights
NYSE
0.0801
-0.0098
-10.90%
Closed 11:53 02/10 EST
OPEN
0.0801
PREV CLOSE
0.0899
HIGH
0.0801
LOW
0.0801
VOLUME
612
TURNOVER
17
52 WEEK HIGH
0.2749
52 WEEK LOW
0.0150
MARKET CAP
--
P/E (TTM)
0.0232
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CELG RT last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at CELG RT last week (0126-0130)?
Weekly Report · 02/02 09:49
Weekly Report: what happened at CELG RT last week (0119-0123)?
Weekly Report · 01/26 09:49
Weekly Report: what happened at CELG RT last week (0112-0116)?
Weekly Report · 01/19 09:53
Weekly Report: what happened at CELG RT last week (0105-0109)?
Weekly Report · 01/12 09:52
Weekly Report: what happened at CELG RT last week (1229-0102)?
Weekly Report · 01/05 09:49
Weekly Report: what happened at CELG RT last week (1222-1226)?
Weekly Report · 12/29/2025 09:48
Weekly Report: what happened at CELG RT last week (1215-1219)?
Weekly Report · 12/22/2025 09:47
More
About CELG-RT
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELG-RT stock methods without spending real money on the virtual paper trading platform.